Akero(US:AKRO) ZACKS·2024-07-16 17:05Core Insights - Akero Therapeutics, Inc. (AKRO) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive outlook for its earnings and potential stock price increase [1][2] - The Zacks rating system is based on earnings estimate revisions, which are crucial for predicting stock price movements [3][4] Earnings Outlook - The company is projected to report earnings of -$3.82 per share for the fiscal year ending December 2024, reflecting a year-over-year decline of 32.2% [5] - Over the past three months, the Zacks Consensus Estimate for Akero Therapeutics has increased by 6%, indicating a positive trend in earnings estimates [5] Investment Implications - The upgrade to Zacks Rank 2 places Akero Therapeutics in the top 20% of Zacks-covered stocks, suggesting a strong potential for stock price appreciation in the near term [7] - The Zacks Rank system maintains a balanced approach, with only the top 20% of stocks receiving favorable ratings, which enhances the credibility of the rating for Akero Therapeutics [6]